Immunologists are investigating ways to destroy lymphocytes (white blood cells of the immune system) that have become cancerous (lymphomas). A current drug Rituximab contains antibodies that bind to the surfaces of these lymphocytes setting them up for destruction by the cancer patient’s own immune system. They are currently seeking ways to modify the antibody’s structure so that it will attract the cancer patient’s “natural killer” (NK) cells to the lymphocytes. Success of this project will bring a multi-faceted immune response against lymphomas and hasten destruction.

Would this discovery be more useful for a) reducing cancer risks, b) correcting/restoring cancer cells to normal, or c) destroying cancerous tissue?